Manufacturing

Pharmaceutical Technology Europe spoke with experts about the developments that have shaped the nanotechnology industry today and the benefits that this technology has to offer the pharmaceutical industry, which remain largely untapped.

A significant increase in the recruitment of contract staff is expected during the next 12 months in the UK biotechnology sector, according to a survey conducted by SRG, which provides personnel to various science-based sectors.

A significant increase in the recruitment of contract staff is expected during the next 12 months in the UK biotechnology sector, according to a survey conducted by SRG.

Eli Lilly, Merck Sharp & Dohme, and Pfizer form the Asian Cancer Research Group, a nonprofit aimed at accelerating research and improving treatment for patients affected with the most commonly diagnosed cancers in Asia.

Merck To Eliminate 15,000 jobs; Tauzin Stepping Down At PhRMA; And More.

RUSNANO, a corporation established by the Russian government to foster the development of nanotechnology, launched a project last week to manufacture targeted-delivery nanodrugs to treat malignant neoplasms.

The Society for Chemical Manufacturers and Affiliates offered its support for a Senate proposal to extend to 2015 current chemical-security standards, the Chemical Facility Anti-Terrorism Standards, which are set to expire this year.

Abbott Completes Acquisition Of Solvay; Merck Names President of Consumer Healthcare; And More.

A joint investment of approximately 28 million Euros ($38 million) for seven projects may bring personalized medicine closer to reality by developing ways to deliver drugs to specific disease sites within the body.

PharmTech's monthly newsletter, Equipment and Processing Report, reviews the Editor's Picks for the February 2010 edition from ABB and David Round.

Pharmaceutical manufacturers that launch ePedigree and serialization initiatives today will improve their competitive positions in the short and long terms.

Drugmakers have many incentives to avoid overfilling their containers, including the scarcity, and correspondingly high cost, of certain cells and ingredients. These concerns highlight the need for techniques that can fill small volumes of product with great accuracy. Many strategies are available to the industry, but which one works best?

Following its $68-billion acquisition of Wyeth, Pfizer is integrating its manufacturing and outsourcing activities (Podcast).

Margaret Hamburg, commissioner of the US Food and Drug Administration, unveiled a new program to improve the efficiency of import inspections.

VaxGen Shareholders Reject OXiGENE Merger; Roche Creates Research Hub In Singapore; And More.

GSK launched a stand-alone unit that will specialize in the R&D and commercialization of medicines for rare diseases.

A highly functioning New Product Planning (NPP) group is a company's first line of defence against losses caused by products that fail to reach the market, according to research and consulting firm Best Practices LLC.

Pfizer's first updated pipeline since its acquisition of Wyeth includes fewer projects than before and is targeted to specific diseases.

Cephalon Buys Mepha; BASi's CEO Retires; and More.

AstraZeneca announced this week that it plans to undertake further restructuring in its research and development operations, resulting in the elimination of 3500 jobs.

Hoping to prevent the deaths of eight million children over the next decade, Bill and Melinda Gates recently committed $10 billion for child-immunization programs in the world's poorest countries.

Strategic rather than tactical considerations are driving biopharmaceutical outsourcing.

Sharing too much-or too little-information can have disastrous onsequences.

FDA impersonators and counterfeit drugs threaten the public's trust in online pharmacies.

Editors' Picks of Pharmaceutical Science & Technology Innovations

A look at the formulation challenges in pancreatic enzyme products.

Vaccine R&D is surging, but continues to raise manufacturing and regulatory challenges.

Regulators and industry move to require inspections of API manufacturing facilities.

When it comes to healthcare rform, we must not overlook investment in innovative technologies.

How to cut time and cost by re-using already submitted documents.